The system was launched late last year, but a preliminary injunction issued by a federal court in California will now block Qiagen from marketing its GeneReader sequencing system in the US. Illumina had filed a patent claim against the system, and the court found that the claim is likely to succeed.

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.

Qiagen has acquired privately held Intelligent Bio-Systems, a developer of next-generation sequencing (NGS) instruments aimed at the clinical research market. IBS’ technology, along with a newly expanded collaboration with bioinformatics provider SAP, is the cornerstone of a new NGS initiative at Qiagen.